Home
  >  
Section 55
  >  
Chapter 54,323

Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112

Chou, T.; Tobinai, K.; Uike, N.; Asakawa, T.; Saito, I.; Fukuda, H.; Mizoroki, F.; Ando, K.; Iida, S.; Ueda, R.; Tsukasaki, K.; Hotta, T.; Aikawa, K.; Matsuda, S.; Nakata, M.; Oshimi, K.; Ohmachi, K.; Ohnishi, K.; Kinoshita, T.; Okamura, S.; Tsukada, J.

Japanese Journal of Clinical Oncology 41(4): 586-589

2011


ISSN/ISBN: 1465-3621
PMID: 21247967
DOI: 10.1093/jjco/hyq245
Accession: 054322466

A multicenter phase III study for untreated multiple myeloma was conducted to investigate a switch-induction chemotherapy with melphalan-prednisolone and vincristine-doxorubicin-dexamethasone followed by randomization on maintenance therapy for patients achieving plateau. Between November 2002 and November 2005, 34 patients were registered. The study was closed early because of poor accrual. Thirty-three eligible patients, with a median age of 65 years (range: 47-77 years) were analyzed for the secondary purpose. For induction therapy, 16 patients were treated with vincristine-doxorubicin-dexamethasone and 17 with melphalan-prednisolone initially. In eight cases, induction therapy was switched because of a poor response. Both regimens were well tolerated, but neutropenia, anorexia, constipation and infection with neutropenia were more frequent for vincristine-doxorubicin-dexamethasone. Best response rates were 44% (95% confidence interval, 20-70) and 47% (95% confidence interval, 23-72), respectively, for vincristine-doxorubicin-dexamethasone and melphalan-prednisolone. Vincristine-doxorubicin-dexamethasone/melphalan-prednisolone switch-induction therapy might be feasible and effective for Japanese patients with multiple myeloma.

PDF emailed within 0-6 h: $19.90